Objectives: Growth hormone (GH) secretory status and GH therapy influence cardiac muscle mass and function. Most patients with Prader-Willi syndrome (PWS) are GH-deficient (GHD), and are at risk to develop obesity-related cardiac problems. Few data exist on the development of cardiac dimensions under GH treatment in PWS. Study Design: In a retrospective study, cardiac dimensions measured echocardiographically in 26 children with PWS before and after 22.9 ± 11.0 months of GH therapy (0.035 mg/kg/day) were compared to those of 13 GHD children treated with GH (0.025–0.035 mg/kg/day) over 13.5 ± 4.2 months. Results: Low-normal left ventricular end-systolic [diastolic] diameter SDS increased in PWS patients (1.41, p < 0.0001 [1.23, p < 0.0001]) and in controls (0.61, p = 0.04 [0.78, p = 0.013]), becoming elevated above normal in 2/26 PWS patients. There was a trend for a higher GH effect on left ventricular end-systolic diameter in PWS (p = 0.071). Mean values of all echocardiographic dimensions remained in the normal range in both PWS patients and controls, before and under GH therapy. Conclusion: The response of cardiac dimensions to GH treatment is similar in PWS patients and GHD controls, with a trend towards more elevated left ventricular parameters in PWS. Therefore, regular echocardiographic assessment may be considered in PWS children with longer treatment duration.

1.
Sacca L, Cittadini A, Fazio S: Growth hormone and the heart. Endocr Rev 1994;15:555–573.
2.
Burman P, Ritzen EM, Lindgren AC: Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr Rev 2001;22:787–799.
3.
Carrel AL, Myers SE, Whitman BY, Eickhoff J, Allen DB: Long-term growth hormone therapy changes the natural history of body composition and motor function in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2010;95:1131–1136.
4.
Whittington JE, Holland AJ, Webb T, Butler J, Clarke D, Boer H: Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J Med Genet 2001;38:792–798.
5.
Tauber M, Diene G, Molinas C, Hebert M: Review of 64 cases of death in children with Prader-Willi syndrome. Am J Med Genet A 2008;146:881–887.
6.
Grugni G, Crino A, Bosio L, Corrias A, Cuttini M, De Toni T, Di Batista E, Franzese A, Gargantini L, Greggio N, Iughetti L, Livieri C, Naselli A, Pagano C, Pozzan G, Ragusa L, Salvatoni A, Trifiro G, Beccaria L, Bellizzi M, Bellone J, Brunani A, Cappa M, Caselli G, Cerioni V, Delvecchio M, Giardino D, Ianni F, Memo L, Pilotta A, Pomara C, Radetti G, Sacco M, Sanzari A, Sartorio A, Tonini G, Vettor R, Zaglia F, Chiumello G: The Italian National Survey for Prader-Willi syndrome: an epidemiologic study. Am J Med Genet A 2008;146:861–872.
7.
Alexander RC, Greenswag LR: Medical and nursing interventions; in Greenswag LR, Alexander RC (eds): Management of Prader-Willi Syndrome. Berlin, Springer, 1995, pp 66–80.
8.
Butler JV, Whittington JE, Holland AJ, Boer H, Clarke D, Webb T: Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: a population-based study. Dev Med Child Neurol 2002;44:248–255.
9.
Rabkin SW, Chen Y, Leiter L, Liu L, Reeder BA: Risk factor correlates of body mass index. Canadian Heart Health Surveys Research Group. CMAJ 1997;157(suppl 1):S26–S31.
10.
Roelandt J, Gibson DG: Recommendations for standardization of measurements from M-mode echocardiograms. Eur Heart J 1980;1:375–378.
11.
Reinken L, van Oost G: Longitudinale Körperentwicklung gesunder Kinder von 0 bis 18 Jahren. Klin Pädiatr 1992;204:129–133.
12.
Kromeyer-Hauschild K, Wabitsch M, Kunze D, Geller F, Geiss HC, Hesse V, von Hippel A, Jaeger U, Johnsen D, Korte W, Menner K, Müller G, Müller JM, Niemann-Pilatus A, Remer T, Schaefer F, Wittchen HU, Zabransky S, Zellner K, Ziegler A, Hebebrand J: Perzentile für den Body-Mass-Index für das Kindes- und Jugendalter unter Heranziehung verschiedener deutscher Stichproben. Monatsschr Kinderheilkd 2001;149:807–818.
13.
Blum WF, Breier BH: Radioimmunoassays for IGFs and IGFBPs. Growth Regul 1994;4(suppl 1):11–19.
14.
Kampmann C, Wiethoff CM, Wenzel A, Stolz G, Betancor M, Wippermann CF, Huth RG, Habermehl P, Knuf M, Emschermann T, Stopfkuchen H: Normal values of M-mode echocardiographic measurements of more than 2,000 healthy infants and children in central Europe. Heart 2000;83:667–672.
15.
SAS System. Release 8.2 Edition. Carey/NC, SAS Institute, 2002.
16.
Lanes R, Gunczler P, Lopez E, Esaa S, Villaroel O, Revel-Chion R: Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone-deficient adolescents. J Clin Endocrinol Metab 2001;86:1061–1065.
17.
Salerno M, Esposito V, Farina V, Radetti G, Umbaldo A, Capalbo D, Spinelli L, Muzzica S, Lombardi G, Colao A: Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after two years of GH replacement therapy: an observational, open, prospective, case-control study. J Clin Endocrinol Metab 2006;91:1288–1295.
18.
Capalbo D, Lo VA, Farina V, Spinelli L, Palladino A, Tiano C, Lettiero T, Lombardi G, Colao A, Salerno M: Subtle alterations of cardiac performance in children with growth hormone deficiency: results of a two years prospective, case-control study. J Clin Endocrinol Metab 2009;94:3347–3355.
19.
Heuschmann D, Butenandt O, Vogel M: Left ventricular volume and mass in children on growth hormone therapy compared with untreated children. Eur J Pediatr 1996;155:77–80.
20.
Szczepanska-Kostro J, Tolwinska J, Urban M, Gardziejczyk M, Glowinska B: Cardiac mass and function, carotid artery intima media thickness, homocysteine and lipoprotein levels in children and adolescents with growth hormone deficiency. J Pediatr Endocrinol Metab 2004;17:1405–1413.
21.
Patel S, Harmer JA, Loughnan G, Skilton MR, Steinbeck K, Celermajer DS: Characteristics of cardiac and vascular structure and function in Prader-Willi syndrome. Clin Endocrinol (Oxf) 2007;66:771–777.
22.
Marzullo P, Marcassa C, Campini R, Eleuteri E, Minocci A, Priano L, Temporelli P, Sartorio A, Vettor R, Liuzzi A, Grugni G: The impact of growth hormone/insulin-like growth factor-I axis and nocturnal breathing disorders on cardiovascular features of adult patients with Prader-Willi syndrome. J Clin Endocrinol Metab 2005;90:5639–5646.
23.
Shulman DI, Root AW, Diamond FB, Bercu BB, Martinez R, Boucek RJ Jr: Effects of one year of recombinant human growth hormone therapy on cardiac mass and function in children with classical growth hormone deficiency. J Clin Endocrinol Metab 2003;88:4095–4099.
24.
Marzullo P, Marcassa C, Campini R, Eleuteri E, Minocci A, Sartorio A, Vettor R, Liuzzi A, Grugni G: Conditional cardiovascular response to growth hormone therapy in adult patients with Prader-Willi syndrome. J Clin Endocrinol Metab 2007;92:1364–1371.
25.
Craig ME, Cowell CT, Larsson P, Zipf WB, Reiter EO, Albertsson WK, Ranke MB, Price DA: Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database). Clin Endocrinol (Oxf) 2006;65:178–185.
26.
Bakker B, Maneatis T, Lippe B: Sudden death in Prader-Willi syndrome: brief review of five additional cases. Concerning the article by U. Eiholzer et al: Deaths in children with Prader-Willi syndrome. A contribution to the debate about the safety of growth hormone treatment in children with PWS (Horm Res 2005;63:33–39). Horm Res 2007;67:203–204.
27.
Nagai T, Obata K, Tonoki H, Temma S, Murakami N, Katada Y, Yoshino A, Sakazume S, Takahashi E, Sakuta R, Niikawa N: Cause of sudden, unexpected death of Prader-Willi syndrome patients with or without growth hormone treatment. Am J Med Genet A 2005;136:45–48.
28.
Pomara C, D’Errico S, Riezzo I, de Cillis GP, Fineschi V: Sudden cardiac death in a child affected by Prader-Willi syndrome. Int J Legal Med 2005;119:153–157.
29.
Ahmad MU, Choy YS, Hung LC, Tan SK, Malinee T, Tan SK, Lim PCK, Othman A, Tan SK, Khoo TB: Dilated cardiomyopathy in two infants with Prader-Willy syndrome and cytogenetically visible microdeletion of 15q11-14. Am J Hum Genet 2001;69 (suppl):282.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.